Science:癌症疗法新思路!抑制癌细胞脱落标志性蛋白 促进免疫系统对癌症发起攻击!

2018-04-02 佚名 “细胞”微信号

日前,一项刊登在国际杂志Science上题为“Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity”的研究报告中,来自美国达纳-法伯癌症研究所和布莱根妇女医院的科学家们通过研究发现,将一种特殊抗体引入到癌症小鼠模型机体中就能有效抑制配体从肿瘤细胞表面逃逸,同时还能促

日前,一项刊登在国际杂志Science上题为“Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity”的研究报告中,来自美国达纳-法伯癌症研究所和布莱根妇女医院的科学家们通过研究发现,将一种特殊抗体引入到癌症小鼠模型机体中就能有效抑制配体从肿瘤细胞表面逃逸,同时还能促进自然杀伤细胞有效杀灭癌细胞。

文章中,研究人员描述了他们所使用的新技术以及该技术的作用原理,此前研究中,研究人员发现,免疫系统难以识别肿瘤的其中一个原因就是肿瘤细胞更倾向于“剥离”宿主机体免疫系统能够识别的癌细胞表面的特殊蛋白;这项研究中,研究人员重点对名为MICA和MICB的两种蛋白进行研究,这两种蛋白是由肿瘤产生,能暴露在裸露的癌细胞表面,正常情况下机体免疫系统能够有效识别这两种肿瘤蛋白。

在免疫系统识别这两种肿瘤蛋白之前,实际上肿瘤会产生一种特殊酶类,将MICA和MICB剔除出癌细胞表面使其脱落,从而就能抑制免疫系统利用这种识别特性来狙杀癌细胞了;随后研究人员深入研究阐明了是否能够找到一种行之有效的方法来抑制肿瘤细胞脱落MICA和MICB两种蛋白,这样一来机体免疫系统就能有效发挥杀灭癌细胞的作用了。

当进行了一段时间的搜索后,研究人员最后将目光锁定到一种名为mAb 7C6的抗体上,当该抗体被应用于肺癌和黑色素瘤小鼠模型上时,其就会促进癌细胞表面MICA和MICB两种蛋白的水平增加,这就表明,肿瘤细胞或许就无法有效脱落MICA和MICB蛋白了,此外,研究者还发现,杀伤性免疫细胞随后就会向肿瘤细胞发起攻击,从而有效抑制肿瘤的增殖,甚至杀灭肿瘤细胞。

最后研究者Lanier表示,这种新技术或能用来帮助机体免疫系统有效抵御肿瘤,而不是通过药物干预手段来直接攻击肿瘤,研究人员认为,诸如这样的疗法未来或有望彻底根治癌症,同时还不会产生太多的毒副作用。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2019331, encodeId=443120193315b, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Dec 02 15:54:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752909, encodeId=f1c21e5290965, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sun Oct 28 13:54:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252486, encodeId=ef2112524860a, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375792, encodeId=2d5f13e579292, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302263, encodeId=ae233022639d, content=好消息.临床研究的新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 03 06:20:27 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-12-02 晓辰
  2. [GetPortalCommentsPageByObjectIdResponse(id=2019331, encodeId=443120193315b, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Dec 02 15:54:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752909, encodeId=f1c21e5290965, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sun Oct 28 13:54:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252486, encodeId=ef2112524860a, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375792, encodeId=2d5f13e579292, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302263, encodeId=ae233022639d, content=好消息.临床研究的新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 03 06:20:27 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-10-28 mnda
  3. [GetPortalCommentsPageByObjectIdResponse(id=2019331, encodeId=443120193315b, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Dec 02 15:54:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752909, encodeId=f1c21e5290965, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sun Oct 28 13:54:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252486, encodeId=ef2112524860a, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375792, encodeId=2d5f13e579292, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302263, encodeId=ae233022639d, content=好消息.临床研究的新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 03 06:20:27 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-04 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=2019331, encodeId=443120193315b, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Dec 02 15:54:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752909, encodeId=f1c21e5290965, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sun Oct 28 13:54:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252486, encodeId=ef2112524860a, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375792, encodeId=2d5f13e579292, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302263, encodeId=ae233022639d, content=好消息.临床研究的新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 03 06:20:27 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-04 jichang
  5. [GetPortalCommentsPageByObjectIdResponse(id=2019331, encodeId=443120193315b, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Dec 02 15:54:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752909, encodeId=f1c21e5290965, content=<a href='/topic/show?id=b103e1424b2' target=_blank style='color:#2F92EE;'>#癌症疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71424, encryptionId=b103e1424b2, topicName=癌症疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e236589107, createdName=mnda, createdTime=Sun Oct 28 13:54:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252486, encodeId=ef2112524860a, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375792, encodeId=2d5f13e579292, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Apr 04 04:54:00 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302263, encodeId=ae233022639d, content=好消息.临床研究的新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue Apr 03 06:20:27 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 易水河

    好消息.临床研究的新方向

    0

相关资讯

PNAS:**反应者!血小板在免疫系统中发挥更大作用

1月31日,发表在PNAS上的一项研究发现,血小板在我们的免疫系统中起着比先前所认为的更重要的作用。除了参与凝血和愈合过程,当病毒、细菌或过敏原进入血液时,血小板还充当了免疫系统的“第一反应者”。

Sci Immun:“寿命时钟”胸腺如何自我再生?

胸腺,很多人认为是与人体无关的退化器官。直到后来发现,它原来是“免疫活性细胞的T细胞培训中心”,体内这种T细胞越多,免疫功能就越强。此外,胸腺还被喻为人的“寿命时钟”,是人体最早开始衰老的器官。1月12日《Science Immunology》杂志发表的一项新研究确定了一种名为BMP4的分子,能促进胸腺的再生。

J Allergy Clin Immun:“训练”免疫系统,缓解食物过敏

美国杜克大学健康研究所的科学家们发现,治疗食物过敏很可能仅仅需要简单地对免疫系统进行一下训练。

Nature:免疫反应如何确定肠道菌群和人体内代谢之间的稳态

发表在《Nature》上面名为“Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism”的文章,为我们揭示了免疫系统如何以不同的形式参与人体肠道菌群和脂质代谢。

免疫系统是先“攘外”还是先“安内”?

最近一直很着迷用“辩证法”来分析免疫系统。比如前段时间写的一篇有关评估健康的博文,也用到类似的图解。所谓辩证,就是用不同的角度(潜力,效率)去观察同一个问题(免疫力)。这里,我不是静态地观察免疫力,而是把它放到时间的长轴上去观察:

J Exp Med:炎症导致的疾病,与某蛋白质的自我切割...

近日,澳大利亚昆士兰大学(UQ)的研究人员发现一种炎症过程在健康细胞中自动关闭的方式,这很可能是阻止多种常见疾病(包括肝脏疾病、阿尔兹海默症和痛风)中不受控炎症造成伤害的关键。现在,他们正在研究手动停止这一过程的方法。该研究已于近日发表在《Journal of Experimental Medicine》上。